{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:55:30Z","timestamp":1786650930849,"version":"build-2736575974"},"reference-count":79,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asian J Androl"],"published-print":{"date-parts":[[2014]]},"DOI":"10.4103\/1008-682x.122591","type":"journal-article","created":{"date-parts":[[2014,4,30]],"date-time":"2014-04-30T07:53:01Z","timestamp":1398844381000},"page":"341","source":"Crossref","is-referenced-by-count":6,"title":["Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer"],"prefix":"10.4103","volume":"16","author":[{"given":"PhilipJ","family":"Saylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1008-682X.122591-1","first-page":"799","volume-title":"Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling","author":"Lewiecki","year":"2009","journal-title":"IDrugs"},{"key":"key-10.4103\/1008-682X.122591-2","first-page":"110","volume-title":"The endothelin axis: emerging role in cancer","author":"Nelson","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"key-10.4103\/1008-682X.122591-3","first-page":"2478","volume-title":"Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer","author":"Nelson","year":"2008","journal-title":"Cancer"},{"key":"key-10.4103\/1008-682X.122591-4","first-page":"177","volume-title":"SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer","author":"Saad","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"key-10.4103\/1008-682X.122591-5","first-page":"1166","volume-title":"Once-daily dasatinib: Expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer","author":"Yu","year":"2011","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.122591-6","first-page":"7421","volume-title":"Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer","author":"Yu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.122591-7","doi-asserted-by":"crossref","unstructured":"Hussain M, Smith MR, Sweeney C, Corn PG, Elfiky A, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. J Clin Oncol 2011; 29(suppl; abstr 4516).","DOI":"10.1200\/jco.2011.29.15_suppl.4516"},{"key":"key-10.4103\/1008-682X.122591-8","doi-asserted-by":"crossref","unstructured":"Smith DC, Smith MR, Small EJ, Sweeney C, Kurzrock R, et al. Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease. J Clin Oncol 2011; 29(suppl 7; abstr 127).","DOI":"10.1200\/jco.2011.29.7_suppl.127"},{"key":"key-10.4103\/1008-682X.122591-9","first-page":"337","volume-title":"Osteoclast differentiation and activation","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"key-10.4103\/1008-682X.122591-10","first-page":"12665","volume-title":"Growth factors in bone matrix.Isolation of multiple types by affinity chromatography on heparin-Sepharose","author":"Hauschka","year":"1986","journal-title":"J Biol Chem"},{"key":"key-10.4103\/1008-682X.122591-11","first-page":"2919","volume-title":"Biochemical markers and skeletal metastases","author":"Demers","year":"2000","journal-title":"Cancer"},{"key":"key-10.4103\/1008-682X.122591-12","first-page":"3361","volume-title":"Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer","author":"Cook","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.122591-13","first-page":"59","volume-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/1008-682X.122591-14","doi-asserted-by":"crossref","unstructured":"Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19.","DOI":"10.1016\/S0092-8674(00)80209-3"},{"key":"key-10.4103\/1008-682X.122591-15","first-page":"1059","volume-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/1008-682X.122591-16","first-page":"2645","volume-title":"Antibody pharmacokinetics and pharmacodynamics","author":"Lobo","year":"2004","journal-title":"J Pharm Sci"},{"key":"key-10.4103\/1008-682X.122591-17","first-page":"633","volume-title":"Population pharmacokinetics of therapeutic monoclonal antibodies","author":"Dirks","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"key-10.4103\/1008-682X.122591-18","first-page":"756","volume-title":"Freedom Trial.Denosumab for prevention of fractures in postmenopausal women with osteoporosis","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.122591-19","first-page":"3161","volume-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","author":"Orwoll","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/1008-682X.122591-20","first-page":"81","volume-title":"Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study","author":"Ellis","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"key-10.4103\/1008-682X.122591-21","first-page":"4875","volume-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.122591-22","first-page":"1125","volume-title":"Randomized, double-blind study of denosumab versus zoledronic Acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","author":"Henry","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.122591-23","first-page":"813","volume-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"key-10.4103\/1008-682X.122591-24","first-page":"5132","volume-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.122591-25","first-page":"4415","volume-title":"Denosumab induces tumor reduction and bone formation in patients with giant-Cell tumor of bone","author":"Branstetter","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.122591-26","first-page":"275","volume-title":"Denosumab in patients with giant-Cell tumour of bone: an open-label, phase 2 study","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.122591-27","first-page":"407","volume-title":"World-wide projections for hip fracture","author":"Gullberg","year":"1997","journal-title":"Osteoporos Int"},{"key":"key-10.4103\/1008-682X.122591-28","first-page":"948","volume-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.122591-29","first-page":"154","volume-title":"Risk of fracture after androgen deprivation for prostate cancer","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.122591-30","first-page":"7897","volume-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.122591-31","first-page":"105","volume-title":"Changes in bone mineral density with age in men and women: a longitudinal study","author":"Warming","year":"2002","journal-title":"Osteoporos Int"},{"key":"key-10.4103\/1008-682X.122591-32","first-page":"152","volume-title":"Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: Interim analysis of a multicenter phase 3 clinical study","author":"Smith","year":"2008","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.122591-33","first-page":"3841","volume-title":"Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/1008-682X.122591-34","first-page":"155","volume-title":"Smoking and fracture risk: a meta-analysis","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"key-10.4103\/1008-682X.122591-35","first-page":"375","volume-title":"A meta-analysis of previous fracture and subsequent fracture risk","author":"Kanis","year":"2004","journal-title":"Bone"},{"key":"key-10.4103\/1008-682X.122591-36","first-page":"737","volume-title":"Alcohol intake as a risk factor for fracture","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"key-10.4103\/1008-682X.122591-37","first-page":"893","volume-title":"A meta-analysis of prior corticosteroid use and fracture risk","author":"Kanis","year":"2004","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/1008-682X.122591-38","first-page":"1029","volume-title":"A family history of fracture and fracture risk: a meta-analysis","author":"Kanis","year":"2004","journal-title":"Bone"},{"key":"key-10.4103\/1008-682X.122591-39","first-page":"989","volume-title":"Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds","author":"Kanis","year":"2001","journal-title":"Osteoporos Int"},{"key":"key-10.4103\/1008-682X.122591-40","first-page":"416","volume-title":"Effect of once-weekly oral alendronate on Bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/1008-682X.122591-41","first-page":"1444","volume-title":"The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study","author":"Diamond","year":"2001","journal-title":"Cancer"},{"key":"key-10.4103\/1008-682X.122591-42","first-page":"2008","volume-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.122591-43","first-page":"1038","volume-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.122591-44","first-page":"1766","volume-title":"Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer","author":"Morabito","year":"2004","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/1008-682X.122591-45","first-page":"745","volume-title":"Denosumab HALT Prostate Cancer Study Group.Denosumab in men receiving androgen-deprivation therapy for prostate cancer","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.122591-46","first-page":"2670","volume-title":"Effects of denosumab on Bone mineral density in men receiving androgen deprivation therapy for prostate cancer","author":"Smith","year":"20","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.122591-47","first-page":"1316","volume-title":"Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer","author":"Smith","year":"2010","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.122591-48","unstructured":"National Osteoporosis Foundation. Osteoporosis in Men. 2005."},{"key":"key-10.4103\/1008-682X.122591-49","first-page":"1513","volume-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.122591-50","first-page":"1995","volume-title":"COU-AA-301 Investigators.Abiraterone and increased survival in metastatic prostate cancer","author":"de","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.122591-51","first-page":"1147","volume-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","author":"de","year":"2010","journal-title":"Lancet"},{"key":"key-10.4103\/1008-682X.122591-52","first-page":"765","volume-title":"Medical Research Council PR04 Collaborators.Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: medical Research Council PR04 (ISRCTN61384873)","author":"Mason","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/1008-682X.122591-53","first-page":"872","volume-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.122591-54","first-page":"2918","volume-title":"Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.122591-55","first-page":"1300","volume-title":"Mrc Pr05 Collaborators.A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)","author":"Dearnaley","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/1008-682X.122591-56","doi-asserted-by":"crossref","unstructured":"Smith MR, Halabi S, Ryan CJ, et al. Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and Bone metastases: results of CALGB 90202 (Alliance). J Clin Oncol 2013; 31 (suppl 6; abstr 27).","DOI":"10.1200\/jco.2013.31.6_suppl.27"},{"key":"key-10.4103\/1008-682X.122591-57","first-page":"879","volume-title":"Zoledronic Acid Prostate Cancer Study Group.Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/1008-682X.122591-58","first-page":"3335","volume-title":"Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain","author":"Ernst","year":"2003","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.122591-59","first-page":"4277","volume-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of Bone pain in men with metastatic prostate cancer","author":"Small","year":"2003","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.122591-60","first-page":"1564","volume-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.122591-61","first-page":"1","volume-title":"Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours","author":"Ford","year":"2013","journal-title":"Health Technol Assess"},{"key":"key-10.4103\/1008-682X.122591-62","first-page":"621","volume-title":"Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with Bone metastases","author":"Xie","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"key-10.4103\/1008-682X.122591-63","first-page":"19","volume-title":"Denosumab versus zoledronic acid for treatment of Bone metastases in men with castration-resistant prostate cancer: A cost-effectiveness analysis","author":"Snedecor","year":"2013","journal-title":"J Med Econ"},{"key":"key-10.4103\/1008-682X.122591-64","first-page":"712","volume-title":"Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and Bone metastases in the United States","author":"Stopeck","year":"2012","journal-title":"J Med Econ"},{"key":"key-10.4103\/1008-682X.122591-65","first-page":"1115","volume-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"key-10.4103\/1008-682X.122591-66","first-page":"527","volume-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"key-10.4103\/1008-682X.122591-67","first-page":"826","volume-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/1008-682X.122591-68","first-page":"2","volume-title":"American Association of Oral and Maxillofacial Surgeons.American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"key-10.4103\/1008-682X.122591-69","first-page":"1674","volume-title":"American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw.Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs","author":"Edwards","year":"2008","journal-title":"J Am Dent Assoc"},{"key":"key-10.4103\/1008-682X.122591-70","first-page":"1341","volume-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","author":"Saad","year":"2011","journal-title":"Ann Oncol"},{"key":"key-10.4103\/1008-682X.122591-71","first-page":"1458","volume-title":"Zoledronic Acid Prostate Cancer Study Group.A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/1008-682X.122591-72","unstructured":"Novartis. Zometa full prescribing information. Package insert. revised 10\/2009."},{"key":"key-10.4103\/1008-682X.122591-73","first-page":"175","volume-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","author":"Anderson","year":"1997","journal-title":"Nature"},{"key":"key-10.4103\/1008-682X.122591-74","first-page":"315","volume-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"key-10.4103\/1008-682X.122591-75","first-page":"327","volume-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","author":"Watts","year":"2012","journal-title":"Osteoporos Int"},{"key":"key-10.4103\/1008-682X.122591-76","first-page":"1187","volume-title":"AFFIRM Investigators.Increased survival with enzalutamide in prostate cancer after chemotherapy","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.122591-77","first-page":"89","volume-title":"Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain","author":"Paes","year":"2010","journal-title":"Semin Nucl Med"},{"key":"key-10.4103\/1008-682X.122591-78","first-page":"213","volume-title":"ALSYMPCA Investigators.Alpha emitter radium-223 and survival in metastatic prostate cancer","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.122591-79","first-page":"39","volume-title":"Denosumab and Bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial","author":"Smith","year":"2011","journal-title":"Lancet"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:24:41Z","timestamp":1786649081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1008-682X.122591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"alternative-id":["122591"],"URL":"https:\/\/doi.org\/10.4103\/1008-682x.122591","relation":{},"ISSN":["1008-682X"],"issn-type":[{"value":"1008-682X","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}